Protalix BioTherapeutics, Inc. (PLX) bonds

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value

$3.05+0.09 (+3.04%)

Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Individual notes, bonds and loans

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Parsed from the XBRL in Protalix BioTherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 20, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PLX.

Revenue growth37.0% · median 133.8%

Gross margin71.2% · median 29.2%

Operating margin29.8% · median -311.0%

Net margin24.3% · median -275.2%

Advertisement
300 × 250

See a number that looks wrong?